# Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-of-once-weekly-semaglutide-1-mg-versus-canagliflozin-300-mg/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Sara Stafford,Peter G. Bech,Adam Fridhammar,Nino Miresashvili,Andreas Nilsson,Michael Willis,Aiden Liu |
| Citations | 10 |
| DOI | 10.1007/s40258-022-00726-z |
| Fields | Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://link.springer.com/content/pdf/10.1007/s40258-022-00726-z.pdf |
| OpenAlex ID | https://openalex.org/W4220936928 |
| PMID | 35344191 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Andreas Nilsson](https://scholariq.org/researchers/andreas-nilsson/)

## Paper journal

- [Applied Health Economics and Health Policy](https://scholariq.org/journals/applied-health-economics-and-health-policy/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.